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Background: Rituximab has increasingly been used for the treatment of hematological malignancies and
autoimmune diseases, and its efﬁcacy and safety are well established. Although clinical trials have
shown conﬂicting results regarding the association of rituximab with infections, an increased incidence
of infections has recently been reported in patients with lymphomas being treated with rituximab.
However, clinical experience regarding the association of rituximab with different types of infection is
lacking and this association has not been established in patients with rheumatoid arthritis.
Methods: All previous studies included in our literature review were found using a PubMed, EMBASE,
and Cochrane database search of the English-languagemedical literature applying the terms ‘rituximab’,
‘monoclonal antibodies’, ‘infections’, ‘infectious complications’, and combinations of these terms. In
addition, the references cited in these articles were examined to identify additional reports.
Results:We performed separate analyses of data regarding the association of rituximabwith infection
in (1) patients with hematological malignancies, (2) patients with autoimmune disorders, and (3)
transplant patients. Recent data show that rituximab maintenance therapy signiﬁcantly increases the
risk of both infection and neutropenia in patients with lymphoma or other hematological malignancies.
On the other hand, data available to date do not indicate an increased risk of infections when using
rituximab comparedwith concurrent control treatments in patientswith rheumatoid arthritis. However,
there is a lack of sufﬁcient long-term data to allow such a statement to be deﬁnitively made, and caution
regarding infections should continue to be exercised, especially in patients who have received repeated
courses of rituximab, are receiving other immunosuppressants concurrently, and in those whose
immunoglobulin levels have fallen below the normal range. Few data are available concerning the risk of
organ transplant recipients developing infections following rituximab therapy. Data from case reports,
case series, and retrospective studies correlate rituximab use with the development of a variety of
infections in transplant patients.
Conclusions: Further studies are needed to clarify the association of rituximab with infection.
Physicians and patients should be educated about the association of rituximab with infectious
complications. Monitoring of absolute neutrophil count and immunoglobulin levels and the
identiﬁcation of high-risk groups for the development of infectious complications, with timely
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 Clinical trials have shown conﬂicting results regarding the
association of rituximab with infections. However, clinical
experience regarding the association of rituximab with different
types of infection is lacking.
 An increased incidence of infections in patients with lymphomas
and rheumatoid arthritis being treated with rituximab has been
recently reported.
 Education of physicians and patients about the association of
rituximab with infectious complications, monitoring of absolute
neutrophil count and immunoglobulin levels, identiﬁcation of
high risk groups for development of infectious complications and
timely vaccination of these groups are needed
1. Introduction
Rituximab (Rituxan1) is a chimeric human–mousemonoclonal
antibody that has been used extensively in the treatment of
hematological malignancies and autoimmune diseases and is US
Food and Drug Administration (FDA) approved for CD20-positive
B-cell non-Hodgkin’s lymphoma (NHL) and for moderate-to-
severe rheumatoid arthritis (RA) not responding to other treat-
ments.1–3More speciﬁcally, rituximab is a human–mouse chimeric
monoclonal antibody (IgG1) that reacts speciﬁcally with the CD20
antigen expressed on more than 95% of normal and malignant B-
cells, inducing complement-mediated and antibody-dependent
cellular cytotoxicity (Fig. 1).4
Treatment with rituximab causes a rapid depletion of pre-B-
and mature B-cells, which remain at low or undetectable levels for
2–6 months before returning to pretreatment levels, generally
within 12 months. There is growing evidence, including an
increased incidence of certain viral infections with the use of
rituximab,5 supporting the notion that rituximab, in addition to its
[(Fig._1)TD$FIG]
Fig. 1. Mechanism of action of rituximab. Rituximab reacts speciﬁcally with the CD20
complement-mediated and antibody-dependent cellular cytotoxicity. There is growing e
inﬂuences T-cell immunity and this may predispose to opportunistic infections. Rituxim
such as delayed-onset cytopenia, particularly neutropenia and hypogammaglobulinemeffect on B cells, also inﬂuences T-cell immunity and predisposes to
opportunistic infections.6–9 Rituximab may cause immunosup-
pression through several other mechanisms such as delayed-onset
cytopenia, particularly neutropenia10 and hypogammaglobuline-
mia, especially when administered for long periods, e.g., in
maintenance therapy.11–13
Clinical trials have shown conﬂicting results regarding the
association of rituximab with infections.5,14–22 An increased
incidence of infections in patients with lymphomas and RA being
treatedwith rituximab has recently been reported.23–26 Pooled data
from 356 patients who received rituximab monotherapy showed
that the incidence rate of infectious events was 30%; 19% of patients
had bacterial infections, 10% viral infections, 1% fungal infections,
and 6% infections of unknown etiology. Severe infections, including
sepsis, occurred in only 1% of patients during the treatment period,
and in 2% during the follow-up period.15 In a recent review27
involving 389 patients from 25 studies, the incidence of serious
infections varied from 2.8% to 45% (mean 12.5%).
Infection in patients treated with rituximab is a multifactorial
process and its incidence becomes difﬁcult to analyze. The age of
the patient, the presence of other medical problems, and
concomitant drug therapies can inﬂuence susceptibility to
infection. Thus, and for purposes of clarity, in this report we
present separate data regarding the association of rituximab with
infection in (1) patients with hematological malignancies, (2)
patients with autoimmune disorders, and (3) transplant patients.
2. Methods
All previous studies included in our literature reviewwere found
using a search of PubMed, EMBASE, and the Cochrane database
(through August 2009) of the English-language medical literature
applying the terms ‘rituximab’, ‘monoclonal antibodies’, ‘infections’,
‘infectious complications’, and combinations of these terms. In
addition, the references cited in these articles were examined toantigen expressed on more than 95% of normal and malignant B-cells, inducing
vidence supporting the notion that rituximab, in addition to its effect on B cells, also
ab may in addition cause immunosuppression through several other mechanisms
ia.
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with infection, we reviewed evidence frommeta-analyses, random-
ized controlled trials, and retrospective studies. We performed
separate analyses of the data regarding the association of rituximab
with infection in (1) patients with hematological malignancies, (2)
patients with autoimmune disorders, and (3) transplant patients.
However, due to the paucity of data regarding the different types of
infections associated with the use of rituximab (bacterial, viral,
fungal, parasitic), we also reviewed the evidence from case–control
studies, case series, and case reports.
3. Rituximab and infection in hematological malignancies
Table 1 outlines the most important studies evaluating
infection in rituximab-treated patients with hematological malig-
nancies.19,23,28–45
In a recent systematic review in patientswith lymphoma, Aksoy
et al. found signiﬁcantly increased rates of infections and
neutropenia in patients who had received rituximab maintenance
therapy comparedwith thosewho had not (8.1% vs. 3.9% and 13.4%
vs. 6.3%, respectively).23 In a similar meta-analysis of randomized
controlled trials (RCT), patients with follicular lymphoma who
underwent rituximab maintenance therapy had more infection-
related adverse events than patients in the observation arm
(relative risk (RR) 1.99, 95% conﬁdence interval (CI) 1.21–3.27).28
This effect wasmore pronouncedwhen only grade 3 or 4 infection-
related adverse events were included in the analysis (RR 2.90, 95%
CI 1.24–6.76).28
Regarding other hematological neoplasias, seven clinical trials
tested rituximab added to the combination of cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) versus CHOP
chemotherapy alone.26 In six studies comparing rituximab with
CHOP (R-CHOP) versus CHOP alone (excluding HIV-1-positive
patients), the rate of infection was higher in one study,35
comparable in three studies,31,32,36 and smaller in one study;34 a
1% increase in infection-associated mortality was found in one
study.33
In HIV patients with lymphoma treated with R-CHOP versus
CHOP, a signiﬁcant 12% increase in the occurrence of opportunistic
infections and infection-related deaths was observed.30 Therefore,
it appears that HIV seropositivity inﬂuences the incidence of
infectious complications in such patients.
Concerning the combination of rituximab with non-CHOP-
containing regimens, no signiﬁcant difference in infection rates
compared to the standard regimen was found in three RCTs.37–39
Nevertheless, such effects depend on the co-administered agent.
For example a combined regimen with ﬂudarabine (associated
with profound T-cell depletion)may substantially increase the risk
of opportunistic infections both in the induction and the
maintenance phase.37,41,46,47
The duration of rituximab therapy may also be important. In
one retrospective study of hematology patients receiving ritux-
imab, duration of rituximab therapy, reduction in IgM after
administration of rituximab, and granulocyte colony-stimulating
factor (G-CSF) administration were risk factors associated with
infection.48
Thus, rituximab signiﬁcantly increases the risk of both infection
and neutropenia in patients with lymphoma or other hematologi-
cal malignancies, and this risk appears also to depend on the co-
administered agent.
4. Rituximab and infection in autoimmune disorders
Table 2 outlines the most important studies evaluating
infection in rituximab-treated patients with autoimmune dis-
orders.24,25,49–55Rituximab is effective in patients with RA with an inadequate
response to methotrexate, for whom conventional disease-
modifying antirheumatic drugs (DMARDS) have failed or who
have received one or more tumor necrosis factor (TNF) inhibitors.
The three pre-approval phase II and phase III RCTs conducted
with rituximab in patients with RA reported low rates of infection,
serious or not.53 The rate of infection was higher with rituximab
use in one RCT,52 and slightly higher in placebo-treated patients in
another study.50 The incidence of serious infections was reported
in one phase IIA RCT only: during a 48-week follow-up, six serious
infections were reported in patients treated with rituximab
regimens versus only one serious infection in a patient being
treated with methotrexate alone; this difference was not statisti-
cally signiﬁcant.56
Further information on the risk of infections associated with
rituximab therapy has emerged from open-label extensions to the
RCTs. No signiﬁcant difference in the rates of infectionwith the use
of rituximab and no cases of tuberculosis (TB), opportunistic
infections, or viral reactivations have been reported in the open-
label RA extension studies to date (Table 2).
A recent study suggested that there were no fatal or
opportunistic infections prior to or after another biological DMARD
(in patients with RA refractory to treatment) following rituximab
treatment.50 In a separate meta-analysis of the three rituximab
clinical trials, the pooled odds ratios (OR) for serious infections at
all doses of rituximab versus placebo did not reveal any
statistically signiﬁcant increased risk (OR 1.45, 95% CI 0.56–
3.73).54
Based on the results presented, treatmentwith rituximab for up
to 3 years appears to be associated with a numerically increased
incidence of infections (including serious infections). However no
statistical difference regarding an increased risk for infection is
evident and the risk appears lower than that associated with the
TNF inhibitors. Long-term controlled data are necessary to allow a
more precise deﬁnition of this risk. Thus, further studies are
needed to elucidate the association of rituximab with infection in
patients with RA, since current data do not indicate an increased
risk of infections when using rituximab compared with concurrent
control treatments.
5. Rituximab and infection in transplant patients
Rituximab off-label use includes organ transplantation. The use
or rituximab has been increasing in the transplant population and
an increasing number of infections have been reported. Few data
are available concerning the risk of organ transplant recipients
developing infections following rituximab therapy. Scemla et al.
reported bacterial, viral, and fungal infection rates at 55.3%, 47.4%,
and 13.2%, respectively, in kidney transplant patientswho received
rituximab therapy.57 In kidney transplant patients who received
rituximab therapy at two different doses (375 mg/m2/week four
times or 1000 mg/m2/week two times), Tsapepas et al. reported a
bacterial infection rate at 48% and 61.1%, respectively, a viral
infection rate at 8.2% and 25.3%, respectively, and a fungal infection
rate at 20% and 8.2%, respectively.58 A recent retrospective study by
Grim et al. observed no increased risk of infectious complications
following rituximab therapy in renal transplant recipients.59
Low-dose rituximab induction therapy in renal transplant
recipients appears to have no inﬂuence on the incidence of
cytomegalovirus (CMV) infection and CMV seroconversion.60
However, because of the high incidence of CMV infection,
especially for CMV-seronegative recipients who received ritux-
imab, anti-CMV prophylaxis therapy needs to be considered.60
In one study of 77 kidney transplant patients who received
rituximab therapy, the incidence of bacterial infection was similar
between these patients and another kidney transplant control
Table 1
Studies regarding infectious complications in patients with lymphoma treated with rituximab
Type of study Author, year [Ref.] Patient characteristics Chemotherapy Comments Outcome
Meta-analysis Aksoy, 2009 [23] Lymphoma Rituximab
maintenance therapy
Signiﬁcantly increased rates of
infections and neutropenia. Infection
rates were 8.1% in patients who had
received rituximab maintenance
therapy vs. 3.9% in those who had not.
Neutropenia rates were 13.4% vs. 6.3%,
respectively (p<0.001)
Meta-analysis of the RCTs
demonstrated that rituximab
maintenance therapy signiﬁcantly
increased the RR of both infection and
neutropenia in patients with
lymphoma
Meta-analysis of RCTs Vidal, 2009 [28] Follicular lymphoma Rituximab Patients undergoing rituximab
maintenance therapy had more
infection-related adverse events than
patients in the observation arm (RR
1.99, 95% CI 1.21–3.27). When only
grade 3 or 4 infection-related adverse
events were included in the analysis,
this effect was even more pronounced
(RR 2.90, 95% CI 1.24–6.76)
RCT phase II Eve, 2009 [29] Previously untreated
mantle cell lymphoma
Fludarabine and
cyclophosphamide
with or without
rituximab
Non-hematological toxicity was similar
between the two treatment arms
RCT Kaplan, 2005 [30] NHL (HIV patients) R-CHOP vs. CHOP 99 patients treated with R-CHOP vs. 51
patients treated with CHOP (infection
rate NR). Presence of opportunistic
infections in the R-CHOP group and
absence of these infections in the CHOP
group
Infection-related death was 14% with
R-CHOP vs. 2% with CHOP (p = 0.035)
RCT Lenz, 2005 [31] NHL Mantle cell R-CHOP vs. CHOP 33% (grade I–II) and 5% (grade III/IV) of
62 patients treated with R-CHOP
developed infections vs. 29% (grade I–
II) and 6% (grade III/IV) of 60 patients
treated with CHOP
NR
RCT Hiddemann, 2005 [32] NHL follicular R-CHOP vs. CHOP 5% of 223 patients treated with R-CHOP
developed infections vs. 7% of 205
patients treated with CHOP
Infection-related death 1.9% with R-
CHOP vs. 0.5% with CHOP
RCT Feugier, 2005 [33],
Coifﬁer, 2002 [34]
DLBCL R-CHOP vs. CHOP 65% (any grade) and 12% (grade III/IV)
of 202 patients treated with R-CHOP
developed infections vs. 65% (any
grade) and 20% (grade III/IV) of 197
patients treated with CHOP
Infection-related death 1.7% with R-
CHOP vs. 1.9% with CHOP
RCT Habermann, 2006 [35] DLBCL R-CHOP vs. CHOP 17% of 318 patients treated with R-
CHOP developed infections vs. 16% of
314 patients treated with CHOP
RCT Pfreundschuh, 2006
[36]
NHL B-cell R-CHOP vs. CHOP 7% of 411 patients treated with R-CHOP
developed infections vs. 8% of 413
patients treated with CHOP
RCT Forstpointner, 2004
[37]
NHL follicular and
mantle cell
Rituximab + FCM vs.
FCM
1.5% (grade III/IV) of 62 patients treated
with R-FCM developed infections vs.
1.5% (grade III/IV) of 66 patients treated
with FCM
RCT Marcus, 2005 [38] NHL follicular Rituximab + CVP vs.
CVP
No difference between the two groups
(162 patients in R-CVP vs. 159 in CVP)
RCT Herold, 2003 [39] Indolent NHL Rituximab + MCP vs.
MCP
No difference in infection rates
between the two groups (55 patients in
R-MCP vs. 51 in MCP)
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Table 1 (Continued )
Type of study Author, year [Ref.] Patient characteristics Chemotherapy Comments Outcome
Controlled clinical trial Dungarwalla, 2008
[40]
14 heavily pre-treated
CLL patients
HDMP  rituximab 2 cases of systemic candidiasis, 2 cases
of aspergillosis, 1 case of VZV, 1 case of
adenovirus, bacteremia. Although
HDMP-R causes little or no
myelosuppression, the addition of
rituximab might have predisposed to
opportunistic infections. However,
heavily pre-treated CLL patients have
an increased susceptibility to infection
intrinsic to the disease. Small series of
patients/caution about conclusions
All patients died (except for the case
with VZV)
RCT phase II Del Poeta, 2008 [41] B-CLL Fludarabine and
rituximab
3 dermatomal herpes zoster infections
and 4 localized herpes simplex
infections
Retrospective study Ennishi, 2008 [42] 64 yo M with follicular
lymphoma stage IVa
(partial response to
treatment); 61 yo M
with diffuse large B-
cell lymphoma stage
1a (complete response
to treatment)
R-CHOP 13 of 90 (14%) patients developed
interstitial pneumonitis during R-CHOP
therapy, compared with none of 105
patients treated with CHOP alone; 2 of
these cases were PCP
All patients responded well to
treatment, and recovered within 2–3
weeks
Retrospective study Lee, 2008 [19] 46 patients with
relapsed indolent or
high-risk aggressive B
cell NHL who received
rituximab (17
patients) or not (29
patients) before
autologous HSCT
Rituximab Post-transplant infectious
complications up to 6 months after
transplantation. Seventeen of 46
patients received rituximab before
HSCT. Three of them suffered from CMV
infection and two of them developed
CMV disease. All of the patients with
CMV disease recovered after
ganciclovir and CMV-speciﬁc
immunoglobulin therapy. Twenty-nine
of 46 patients without rituximab
treatment before HSCT did not develop
CMV after HSCT. Risk of CMV infection
after autologous HSCT higher in
rituximab-treated patients (17.6% vs.
0%, p = 0.045). Risk of CMV disease had
higher trend with rituximab therapy
than without rituximab therapy (11.7%
vs. 0%, p = 0.131)
All 3 cases responded to ganciclovir
combined with CMV-speciﬁc
immunoglobulin
RCT phase III Van Oers, 2006 [43] Relapsed/resistant
follicular lymphoma
R-CHOP Upper respiratory tract infections
mostly
RCT phase III Ghielmini, 2005 [44] Mantle cell lymphoma R-CHOP One patient experienced three episodes
of pneumonia, 1 case of hepatitis, 1 case
of septic shock
RCT phase II Hainsworth, 2003 [45] CLL/SL Staphylococcus aureus pneumonia, 1
patient; localized herpes zoster, 1
patient; and gastroenteritis, probably
viral, 1 patient
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL, chronic lymphocytic leukemia; CVP, cyclophosphamide, vincristine, and prednisone; CMV, cytomegalovirus; DLBCL, diffuse large B-cell lymphoma; FCM,
ﬂudarabine, cyclophosphamide, and mitoxantrone; HDMP, high-dose methylprednisolone; HIV, human immunodeﬁciency virus; HSCT, hematological stem cell transplantation; M, male; MCP, mitoxantrone, chlorambucil, and
prednisolone; NHL, non-Hodgkin lymphoma; NR, not reported; PCP, Pneumocystis jiroveci (carinii) pneumonia; R, rituximab; RCT, randomized controlled trial; RR, relative risk; SL, small lymphocytic lymphoma; VZV, varicella zoster
virus; yo, year-old.
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Table 2
Clinical trials and open label studies that report incidence of infections with use of rituximab in patients with rheumatoid arthritis
Type of study Author, year
[Ref.]
Patient charac-
teristics
Immunosuppression F/u of study
duration
Comments Outcome
Clinical trial Lafyatis,
2009 [49]
Diffuse
cutaneous
systemic
sclerosis
Rituximab 6 months No signiﬁcant infections were noted in this pilot
study
Treatment with rituximab appeared to be safe and
well tolerated among patients with dcSSc
Clinical trial Genovese,
2009 [50]
Patients with
advanced RA
many of whom
had previously
been treated
with multiple
RA therapies,
including
biologicals prior
to receiving
rituximab, and
then withdrew
from clinical
trials and
subsequently
received further
biological
therapy
Biological DMARD
after rituximab
treatment
In 185 patients who received rituximab plus another
biological DMARD 13 SIEs (6.99 events/100 patient-
years) occurred following rituximab, but prior to
another biological DMARD. 10 SIEs (5.49 events/100
patient-years) occurred following another biological
DMARD. SIEs were of typical type and severity for RA
patients. No fatal or opportunistic infections
The size of the sample and limited follow-up restricts
deﬁnitive conclusions about safety in B-cell depleted
patients receiving additional biological DMARDs
DANCER RCT
(phase IIB)
Emery, 2006
[51]
Patients with RA MTX +/- rituximab 24 weeks 42/149 (28%) of patients whowere treated withMTX
developed infections and 2/149 (1%) developed
serious infections. 50/142 (35%) of patients who
were treated with MTX + rituximab (500 mg)
developed infections and 0/142 (0%) developed
serious infections. 67/192 (35%) of patients who
were treated with MTX + rituximab (1000 mg)
developed infections and 4/192 (2%) developed
serious infections. Type and severity of infections
were similar across all three treatment arms. The
most common infections were respiratory tract
infections, urinary tract infections, and
nasopharyngitis. The overall rate of serious
infections (events/100 patient-years) was 3.19 for
MTX alone and 4.74 for rituximab 1000 mg
Of the 6 serious infections, 2 occurred in the MTX
monotherapy group (1 each of pneumonia and
respiratory tract infection) and 4 occurred in the
rituximab 1000mg group (2 cases of pyelonephritis
and 1 case each of bronchitis and epiglottitis); all
serious infections were reported to have resolved
without sequelae
Phase IIA Edwards,
2004 [52]
Patients with RA MTX +/- rituximab,
cyclophosphamide +
rituximab
24 weeks 1/40 (3%) of patients who were treated with MTX
developed serious infections. 2/40 (5%) of patients
who were treated with rituximab (1000 mg)
developed serious infections. 2/41 (5%) of patients
who were treated with cyclophosphamide +
rituximab (1000mg) developed serious infections. 0/
40 (0%) of patients who were treated with MTX +
rituximab (1000mg) developed serious infections. In
total 4 patients who had received rituximab
developed serious infections (2 had septic arthritis, 1
of whom also had Staphylococcus aureus-related
septicemia; 1 had 2 episodes of Pseudomonas
aeruginosa pneumonia; and 1 had
bronchopneumonia)
One patient in the rituximab group with serious
infection (bronchopneumonia) subsequently died,
although death may have been related to
concomitant ischemic/vascular heart disease
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Table 2 (Continued )
Type of study Author, year
[Ref.]
Patient charac-
teristics
Immunosuppression F/u of study
duration
Comments Outcome
Phase IIA extension Edwards,
2004 [52]
Patients with RA MTX +/- rituximab,
cyclophosphamide +
rituximab
24 weeks 0/37 (0%) of patients who were treated with MTX
developed serious infections. 1/38 (3%) of patients
who were treated with rituximab (1000 mg)
developed serious infections (1 case of
gastroenteritis). 0/37 (0%) of patients who were
treated with cyclophosphamide + rituximab (1000
mg) developed serious infections. 1/39 (3%) of patients
who were treated with MTX + rituximab (1000 mg)
developed serious infections (1 case of pyelonephritis)
NR
REFLEX RCT
(phase III)
Cohen, 2006
[53]
Patients with RA MTX +/- rituximab 24 weeks 79/209 (38%) of patients who were treated with MTX
developed infectionsand1/209 (3%)developedserious
infections. 126/308 (41%) of patientswhowere treated
withMTX + rituximab (1000mg) developed infections
and 7/308 (2%) developed serious infections. The
overall infection rate (events/100 patient-years) was
slightlyhigher inplacebo-treatedpatients (154.6) than
in rituximab-treated patients (138.2). The most
common infections observed in both groups were
upper respiratory tract infections, nasopharyngitis,
urinary tract infections, bronchitis, and sinusitis. Rates
of serious infections were 3.7/100 patient-years for
placebo and 5.2/100 patient-years for rituximab; no
statistical comparison of this difference was reported
Of 7 serious infections that occurred in the rituximab-
treated patients, 6 (1 case each of gastroenteritis,
pyelonephritis, cat-bite infection, inﬂuenza, fever of
unknown etiology, and de novo hepatitis B (HBV))
resolved without sequelae, while the other infection
(gangrenous cellulitis) resulted in amputation of a toe
Open label trial Keystone,
2007 [54]
Ongoing follow-
up study of all
patients enrolled
in the three
original clinical
trials (2 phase II
and 1 phase III)
who had an
incomplete
response to or
were intolerant
of TNF inhibitors
Rituximab vs. control
group
No evidence to date for any increase in the incidence of
infections and serious infections, with all patients
having received at least 2 courses of rituximab.25 Rates
of infection (events/100patient-years)were 83, 83, 80,
and 88 for patients who had received 1, 2, 3, or 4
courses of rituximab, respectively; the corresponding
rates for serious infections were 4.1, 4.6, 5.6, and 8.0
events/100 patient-years. Rates of infections and
serious infections appear relatively stable with
increasing courses of rituximab, however the extent of
observation for patients receiving multiple courses of
treatment is inevitably less than that for single-course
treatment. Longer follow-up data is necessary.
Irrespective of the number of courses of rituximab,
serious infections occurred most often during the ﬁrst
3months after administration and declined thereafter.
Overall, 68 of 1039 patients (7%) in the all-exposure
population experienced a total of 78 serious infections
following treatment with rituximab. The most
common infections reported were upper respiratory
tract infection,nasopharyngitis, urinary tract infection,
bronchitis, and sinusitis. No incidences of
opportunistic infections or tuberculosis were
observed. The serious infection rate after course 1 (5.1
per 100 patient-years) remained stable through
additional courses. The proportion of patients with
circulating IgMand IgG levels below the LLN increased
with subsequent courses; however, serious infection
rates in these patients (5.6 per 100 patient-years in
patients with low IgM levels and 4.8 per 100 patient-
years in patientswith low IgG levels)were comparable
with those in patients with immunoglobulin levels
above the LLN (4.7 per 100 patient-years)
Three serious infections were fatal. Two occurred
between course 1 and course 2; 1 patient had
bronchopneumonia and a second patient had
neutropenic sepsis following concomitant treatment
with trimethoprim. The third infection-related
fatality occurred after course 2, from septic shock in a
54-year-old female diabetic patient with a history of
sepsis and recurrent urinary tract infections
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rate was signiﬁcantly lower, and the rate of fungal infection was
signiﬁcantly higher in the rituximab group.61 Nine out of 77
patients (11.68%) died after rituximab therapy, of which seven
deaths (9.09%) were related to an infectious disease, compared to
1.55% in the controls (p = 0.0007).61
An increased incidence of JC infection has also been described in
transplant patients who receive rituximab.61 Thus, after kidney
transplantation, the use of rituximab is associated with a high risk
of infectious disease and death related to infectious disease, and
the independent predictive factors for infection-induced death
were recipient age, bacterial and fungal infections, the combined
use of rituximab, and anti-thymocyte globulin given for induction
or anti-rejection therapy.61
In conclusion, although few data are available regarding the
association of rituximab with infection in organ transplant
recipients, data from renal transplant patients suggest an increased
risk of infection with the use of rituximab in this population.
6. Types of infection
Table 3 outlines the most important types of infection
associated with rituximab use.5,16,19,21,30,36,41,42,44,45,49,50,53,54,59,
62–122
In a systematic review of the literature, Cornely et al.123
analyzed 992 patients treated with either alemtuzumab, ritux-
imab, or both; 409 patients (41.2%) were treated with alemtuzu-
mab, 535 (53.9%) with rituximab, and 48 (4.9%) with both. The
overall number of opportunistic infections (OI) diagnosed was 299
(30.1%). Etiologies were distributed as follows: 109 (36.5%)
infections of unknown or unspeciﬁed origin, 100 (33.4%) viral
reactivations, 44 (14.7%) bacterial infections, 26 (8.7%) fungal
infections, 11 (3.7%) protozoal infections, and nine (3.0%) viral
infections. Viral reactivations were most frequently due to CMV
(n = 58, 19.4%), herpes simplex virus (HSV; n = 30, 10.0%), varicella
zoster virus (VZV; n = 11, 3.7%), and Epstein–Barr virus (EBV; n = 1,
0.3%). Pneumonias accounted for 15.1% (n = 45) of observed
bacterial infections, and included 11 Pneumocystis jiroveci pneu-
monia (PCP) cases (3.7%) and 37 (12.4%) blood stream infection
cases. Death attributable to OI occurred in 20 patients (2%).
Optional prophylaxis of viral infections was reported in eight
articles (n = 404, 40.7%), and optional prophylaxis for PCP in nine
articles (n = 435, 43.9%).123
From our review of the literature a broad spectrum of infections
has been associated with rituximab use in clinical trials, including
respiratory tract infections (e.g., bronchopneumonia, nasophar-
yngitis, bronchitis, and sinusitis),53 bacteremia,53 sepsis,52,53
urinary tract infections (including pyelonephritis),52,53 gastroen-
teritis,52 cellulitis,53 septic arthritis,53 cat-bite infection,53 inﬂuen-
za,40,41 de novo hepatitis B (hepatitis B virus (HBV)),41 herpes
zoster,40 HSV infection,40 adenovirus infection,40 systemic candi-
diasis,56 and aspergillosis.25 At the time of writing, we could ﬁnd
no published reports of TB in rituximab-treated patients in clinical
trials.
Data from case reports, case series, and retrospective studies
also correlate rituximab use with the development of a variety of
bacterial, viral, fungal, and parasitic infections (Table 3).
7. Bacterial infections
Representative bacterial infections attributed to rituximab use
are shown in Table 3. A small increase in serious bacterial
infections in RA patients receiving rituximab l000 mg has been
reported.24 In addition, an increase in the rate of serious infections
was seen in a cohort of 78 patients with RA who received a TNF-a
blocking agent after rituximab treatment.50 Thus, sinopulmonary
Table 3
Cases in which addition of rituximab was likely associated with the development of infection
Infection No. of patients Pathogens (n) References
Bacterial infections
Sinopulmonary infection ND Pneumonia (7), Staphylococcus aureus
pneumonia (1), Streptococcus
pneumoniae pneumonia (1), bronchitis
(1), upper respiratory tract infections,
nasopharyngitis, bronchitis, and
sinusitis
30, 36, 50, 53, 54, 59, 62–64
Bacteremia ND Septic shock (3), bacteremia (5) 30, 36, 44, 54, 59, 64
Bacterial diarrhea ND Shigella (1) 50
Urinary tract infections ND No pathogens reported, pyelonephritis 53, 54, 59
Skin infections ND Erysipelas, gangrenous cellulitis 50, 53, 59
Bone and joint infections 2 Infection of right hip (1), septic
polyarthritis with Ureaplasma
urealyticum (1)
50, 65
Dental abscess 1 49
Listeriosis 1 81
Cat scratch disease 1 53
Mycobacterial infections
Other non-tuberculous mycobacteria 4 Bacteremia caused by Mycobacterium
wolinskyi (1), M. avium pleuritis (1), M.
avium bacteremia (1), disseminated M.
kansasii infection (1)
66, 67
Viral infections
CMV disease 26 CMV esophagitis (1), pneumonia (6),
and enterocolitis (4), disseminated
CMV infection (1)
5, 19, 21, 59, 63, 68–71, 101
VZV 13 5, 41, 44, 45, 72–74, 101, 112
HSV 6 Disseminated HSV2 (1) 41, 63, 75
Hepatitis ND Not speciﬁed (3), de novo hepatitis B
(2), HBV reactivation (21 cases in
HBsAg-neg patients), HCV (2), HEV
infection (1)
5, 44, 45, 53, 76–94, 107, 119, 120, 122
Gastroenteritis 4 50, 53, 95
Parvovirus 2 96, 97
Enterovirus 3 Enteroviral meningoencephalitis 98–100
Echovirus 1 112
JC virus 76 52 patients had lymphoproliferative
disorders, two had SLE, one had
rheumatoid arthritis (and
oropharyngeal cancer that had been
treated previously with chemotherapy
and radiotherapy), one had idiopathic
autoimmune pancytopenia, and one
patient with NHL had a concomitant
autoimmune hemolytic anemia
101–104
BK virus 1 BK virus CNS infection 105, 106
RSV 2 107, 108
West Nile virus 3 109–111
Inﬂuenza A virus 2 53, 112
Fungal infections
Fungal infections (not speciﬁed) Fungal pneumonia 30
Candida infections 4 esophagitis (1), candidemia (3) 30
Pneumocystis jiroveci (carinii) 13 Pneumonia 30, 42, 63, 113–116
Aspergillus spp 4 Aspergillosis 16, 117–119
arasitic infections
Babesia microti 8 Babesiosis 121
CMV, cytomegalovirus; CNS, central nervous system; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; HBsAg, hepatitis B surface antigen; HSV, herpes
simplex virus; ND, not determined; NHL, non-Hodgkin lymphoma; RSV, respiratory syncytial virus; SLE, systematic lupus erythematosus; VZV, varicella zoster virus.
T. Kelesidis et al. / International Journal of Infectious Diseases 15 (2011) e2–e16e10infections are the most common bacterial infections that have
been described in associationwith the use of rituximab, but further
data from randomized controlled studies are needed to establish
this association.
8. Mycobacterial infections
Several recent studies suggest that peripheral B cells are
important in the host defense against mycobacteria.30,66,67 Past
history suggestive of TB was an exclusion criterion in the clinical
trials of rituximab in RA, and in the vast majority of cases, study
patients had previously received TNF inhibitors; nevertheless no
reactivation of TB occurred. In NHL clinical trials where history ofTB was not an exclusion criterion, no evidence of an increased
incidence of TB was noted.5 Infection with other mycobacteria has
rarely been associated with rituximab. More speciﬁcally, bacter-
emia caused by Mycobacterium wolinskyi or Mycobacterium avium,
M. avium pleuritis, and disseminated Mycobacterium kansasii
infections have all been described.66,67 Since it is not clear
whether rituximab or other immunosuppressants that were
simultaneously administered promoted disease progression or
causedmycobacterial disease, clinicians should remain vigilant for
mycobacterial infections in patients selected for these therapies.
Thus, there is an open issue regarding TB screening prior to
rituximab initiation. The authors believe that such screening
should be performed.
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Data on the true incidence of viral infections after rituximab
therapy are poor. Co-administration with other cytotoxic chemo-
therapeutic agents and the intensity and duration of T-cell-
mediated immune suppression are signiﬁcant cofactors increasing
the infectious risk.41 Humoral dysfunction related to rituximab
therapy may cause loss of neutralization of free viral particles by
speciﬁc antibodies and an increase in serious viral infections; this
hypothesis needs further investigation.
Reactivation of chronic HBV infection is one of the most
frequently reported serious viral infections.80,82,85–89,107,120 In one
RCT, opportunistic viral infections reported included three
dermatomal herpes zoster infections and four localized herpes
simplex infections.5 Many isolated cases of other viral infections
e.g. CMV, VZV, West Nile virus, inﬂuenza A, JC virus, BK virus,
parvovirus, and enterovirus have been associated with rituximab
use (Table 3).5
Upper respiratory tract viral infections were most frequently
reported, however in most studies infection sites were not
speciﬁed. In a review of 64 cases of severe viral infection after
rituximab treatment, the most frequently experienced viral
infections were HBV (39.1%, n = 25), CMV (23.4%, n = 15), VZV
(9.4%, n = 6), and others (28.1%, n = 18).5
In conclusion, it is still unclear whether rituximab adds to the
risk of viral infection above that conferred by chemotherapy alone;
this association has been studied mainly with particular viral
infections including HBV, hepatitis C virus (HCV), herpes virus, and
JC virus infection.
10. HBV reactivation
A recent review of the literature revealed that themost frequent
viral infection complicating rituximab therapy for lymphoma was
hepatitis B infection. HBV reactivation accounted for 39% of the
reported cases, resulting in a high mortality of 52% due to hepatic
failure.5,77,124 There are increasing reports of HBV reactivation
following rituximab therapy, either when used alone or in
combination with chemotherapy.125 While the addition of
rituximab to CHOP chemotherapy may increase the risk of HBV
reactivation, the precisemagnitude of the increase is not clear with
the available data.80,82,85–89,107,120 The use of rituximab in hepatitis
B surface antigen (HBsAg)-positive patients can be continued
provided they receive a prophylactic antiviral for a prolonged
duration (up to 6 months) after cessation of chemotherapy.80
With the recent increase in rituximab use, HBV reactivation has
been increasingly reported, even in patients who were thought to
have cleared HBV (Table 3).80,92 In a recent study of lymphoma
patientswithpriorresolvedhepatitisB,amongHBsAg-negative/anti-
hepatitisBcore(HBc)-positivediffuselargeB-cell lymphoma(DLBCL)
patients treated with R-CHOP, 25% developed HBV reactivation.122
In addition to the use of rituximab, other potential factors
associatedwithHBVreactivation include theabsenceofanti-HBsand
male sex.5,77,124 In one report it was shown that R-CHOP therapy for
lymphoma can increase the levels of serumHBVDNA and the risk of
intrafamilialHBV infectionwhengiven toHBVcarriers.126 Therefore,
HBV reactivationmay occur in the setting of rituximabuse, and close
monitoring of HBV DNA and liver function testing during rituximab
therapyforat least6monthsafter thecompletionofadministration is
required, with an alternative approach of prophylactic antiviral
therapy to prevent this potentially fatal condition.
11. HCV reactivation
Rituximab-related liver dysfunction has not been described in
HCV-positive patients receiving rituximab combination chemother-apy.127 Rituximab was reported to increase HCV viral load and
alanine aminotransferase (ALT) levels in patients with HCV-related
cryoglobulinemia (ALTwas increased10-foldandHCVviral loadwas
increased 10-fold in one case)128 and lymphoma (ALTwas increased
25-fold in one case and HCV viral load was increased 5–10-fold in
ﬁve cases).129 Therefore, combined use of rituximab with chemo-
therapy poses an additional risk for exacerbation of HCV infection.
The inﬂuence of rituximab on HCV replication is not well
understood. In one case, rituximab therapy for gastric cancer in a
renal transplant recipient with chronic hepatitis C was complicat-
ed by cholestatic injury, an active hepatitis C replication with very
high HCV RNA levels (increase of 1000-fold in HCV viral load after
rituximab), and liver insufﬁciency.129 In two patients who
underwent ABO-incompatible renal transplantation and who
received rituximab and had positive HCV RNA, cholestatic hepatitis
C did not occur, but double-ﬁltration plasmapheresis (DFPP) and
cyclosporine failed to reduce hepatitis C viremia.130 Another
patient with refractory thrombotic thrombocytopenic purpura and
membranoproliferative glomerulonephritis successfully treated
with rituximab developed hepatitis C virus reactivation.93 In
another study of ﬁve HCV-infected patients with B-cell NHL
undergoing treatment with rituximab-combination, all patients
showed a signiﬁcant increase in serum HCV RNA levels (at least 3-
fold) with no occurrence of liver dysfunction.131 Two of these
patients received regimens without prednisone, suggesting that
increased HCV viremia was associated not only with corticosteroid
use, but also with anticancer agents or rituximab.132 On the other
hand, in one study, all seven patients who were HCV RNA-positive
at the time of rituximab therapy for the treatment of transplant
glomerulopathy, did not have signiﬁcantly increased HCV RNA
viremia or elevated levels of liver enzymes in the follow-up.63
In another report, 35 HCV-positive patients with DLBCL received
rituximab-containing combination regimens without any hepato-
toxicity; considering the short follow-up period of their study such
toxicity might have been missed.132 In another study of 44 HCV-
positive patients with DLBCL treated with CHOP/CHOP-like regi-
mens+- rituximab, highviral load and evidence of active hepatitis or
cirrhosis at liver biopsy was associated with more frequent hepatic
failure under treatment and reduced survival.132 Concomitant
administration of R-CHOP plus anti-HCV treatment with pegylated
interferon and ribavirin in four patients with HCV infection and
DLBCL in the same study, resulted in excessive hematological
toxicity.132 On the other hand, sequential treatment with pegylated
interferon plus ribavirin 3 months after chemotherapy in three
patients was found effective, better tolerated, and resulted in a high
rate of complete virus clearance.133,134
The lack of correlation between levels of HCV RNA and the
extent of liver damage and variability of HCV RNA levels over time,
limit strong conclusions regarding the association of rituximab
with HCV infection and liver damage.128,129,132 Kamar et al. found
that rituximab therapy was not associated with a ﬂare-up of
chronic HCV infection in kidney transplant patients.61 Finally,
although HCV viral load can increase after rituximab treatment,5
rituximab has been successfully used in HCV-associated cryoglo-
bulinemia.5,128 This indicates that rituximab may be an effective
treatment for immunologic manifestations of HCV infection.
In summary, the association of rituximab with HCV infection
remains very complex since rituximab may exacerbate HCV
infection, but in other cases it has been used for the treatment
of HCV-related autoimmune phenomena. Physicians should
monitor HCV viral load during rituximab therapy.
12. Herpes infection
Infections with herpes viruses such as CMV, VZV, and HSV have
been described in association with rituximab use.5,19,21,41,44,45,59,63,
T. Kelesidis et al. / International Journal of Infectious Diseases 15 (2011) e2–e16e1268–74,101,112 The most common herpes virus associated with
rituximab is CMV and 26 cases have been described in the
literature.5,19,21,59,63,68–71,101 In cases where CMV infection was
speciﬁed, CMV enterocolitis, pneumonitis, and esophagitis were
described (Table 3).
EBV infection has not been associatedwith rituximab to date. In
one case with disseminated EBV infection, rituximab was
ineffective in treating central nervous system infection with
EBV.5 Other data suggest that EBV persists in cell populations not
depleted by rituximab, such as EBV-infected oropharyngeal
epithelial cells.135 Finally, 13 cases of infection with
VZV5,41,44,45,72–74,101,112 and ﬁve cases of HSV41,63,75 have been
described in association with rituximab therapy (Table 3).
However, data from randomized controlled studies are needed
to establish the association of rituximab use with the development
of infections with herpes viruses.
13. Progressive multifocal leukoencephalopathy
(PML)––JC virus
As of July 29, 2008, there were 76 reports in the manufacturer’s
global safety database of conﬁrmed or suspected PML in patients
receiving rituximab for any indication (69 in oncology indications,
one autoimmune hemolytic anemia, ﬁve in other autoimmune
disorders, and one in an unknown indication).136 In one study
rituximab was associated with a delay in the development of PML
in HIV-negative patients with lymphoproliferative disorders
treated with rituximab compared to patients treated with similar
chemotherapeutic regimens without rituximab.137 According to a
report by the FDA, a total of 23 cases of PML have been documented
in patients on rituximab for hematological malignancies mostly in
combination with chemotherapy or stem cell transplantation.1
Carson et al. reported 57 rituximab-associated PML cases in
HIV-negative patients. Median time from last rituximab dose to
PML diagnosis was 5.5 months (range 0.3–66.0) and the overall
incidence of fatality was 90%.104 Kamar et al. showed that the
incidence of JC viremia in rituximab-treated solid-organ transplant
patients was 5.5%.61 The exact role of rituximab in the develop-
ment of PML is unclear, as humoral immunity is thought to be of
little importance in the latency of JC virus, although the loss of the
B-cell antigen presenting cell functionmay be critical. The effect of
rituximab on T-lymphocyte function as a potential mechanism of
JC virus reactivation remains an area of active inquiry.138 Thus, the
causal relationship between PML and rituximab remains unclear.
14. Fungal infections
Humoral immune deﬁciencies increase the risk for opportunis-
tic fungal infection, and a reduction in antigen-speciﬁc cellular
immunity impairs host protection against fungi. A recent study
demonstrated that the addition of rituximab to CHOP increased the
risk of fungal infection in a very elderly population.30 Pneumocystis
jiroveci (previously known as Pneumocystis carinii) pneumonia
(PCP) may occur in a variety of hematological diseases.115
Although PCP has not been reported in the rituximab treatment
arm of large RCTs, based on data from small trials, retrospective
studies, and case reports, 13 cases of PCP have been described in
the literature in association with rituximab use in patients with
hematological malignancies.30,42,63,113–116 Although these patients
were also receiving other immunosuppressive medications, the
strong temporal relationship between the rituximab infusions and
the onset of the disease suggests that rituximab played a decisive
role in the development of the opportunistic infection. Another
study showed that the addition of rituximab to CHOP-like
regimens, such as CHOP and CHOP-14, with or without etoposide,
increased the incidence of PCP (13% in the rituximab arm vs. 4% inthe other arm).30 No cases of PCP have been reported in patients
with autoimmune disorders receiving rituximab as treatment.
Four case reports have been published that describe the
occurrence of aspergillosis; one in a patient with autoimmune
thrombocytopenic purpura and two in patients with post-
transplant lymphoproliferative disorders that were treated with
rituximab.139 Four cases of Candida infection have also been
described in association with use of rituximab.16,117–119 As all
these patients received extensive additional immunosuppressive
treatment, the exact role of rituximab is difﬁcult to deﬁne.
However, experiments in B-cell deﬁcient mice are in line with a
mild impairment in antifungal immunity.139
The possibly increased susceptibility to P. jiroveci and fungal
infection with the use of rituximab may suggest the need to
administer prophylactic treatment with antifungals and/or tri-
methoprim–sulfamethoxazole during R-CHOP therapy. Due to the
high incidence of Aspergillus and Candida infection, itmay bemore
appropriate to use itraconazole or posaconazole rather than
ﬂuconazole as primary prophylaxis in these patients.140
15. Parasitic infections
Parasitic infections have rarely been described in association
with rituximab use, although eight cases of babesiosis were
described in one study. The authors concluded that rituximab
effects on naive B cells that are responsible for antibody production
in response to a new babesial infection could be involved.121 More
data are needed to elucidate the possible association of inﬂiximab
use with parasitic infections.
16. Immunization effects
The response to vaccination after rituximab could be reduced
since rituximab causes B-cell depletion;141 it is recommended that
any vaccinations should be given before initiating treatment. A
single study found that humoral responses to inﬂuenza vaccination
were lower among patients treatedwith rituximab compared to RA
patients who had received non-biological DMARDs and healthy
controls.142 Data from a recent RCT suggest that patients with RA
treatedwith rituximab can be effectively and safely vaccinated, but
tomaximize response, polysaccharide and primary immunizations
should be administered prior to rituximab infusions.143 A recent
clinical trial showed that rituximab reduces humoral responses
following inﬂuenza vaccination in RA patients, with a modestly
restored response 6–10 months after rituximab administration.143
Recent studies suggest that anti-tetanus immune responses are
decreased shortly after rituximab treatment, while immune
responses to neoantigens and polysaccharides, which are B-cell-
dependent, are decreased following rituximab treatment.142
Despite the suboptimal response, appropriate vaccination (such
as against inﬂuenza or pneumococcus) should be administered
when indicated.142,143 Due to the paucity of data on the use of live
attenuated vaccines while on rituximab, such vaccines should
preferably be administered prior to rituximab use.
17. Limitations
We identiﬁed certain limitations in the studies that have
examined the association of rituximab with infection. Firstly, the
true infection rates may be higher than those reported in clinical
trials since minor infections (grade 1 and grade 2) are possibly
overlooked both by the patients and the doctors, and are under-
reported. In certain reports (mostly case reports) authors did not
provide adequate data regarding the strength of association of
rituximab with infection and thus we could not independently
analyze the strength of evidence regarding this association in these
T. Kelesidis et al. / International Journal of Infectious Diseases 15 (2011) e2–e16 e13cases. Furthermore, variances in reporting rates of neutropenia,
immunoglobulin levels, infections as adverse events by the
doctors, and the heterogeneity of the trials, the different patient
selection criteria, and the different extent of bone marrow
involvement by different subtypes of lymphomas may account
for the differences in infection rates in clinical trials.
18. Conclusions
In conclusion, recent data show that rituximab maintenance
therapy signiﬁcantly increases the risk of both infection and
neutropenia in patients with lymphoma or other hematological
malignancies. Novel prophylaxis and/or pre-emptive treatment
strategies should be tailored for these patients when treated with
rituximab. On the other hand, data available to date do not indicate
an increased risk of infectionwhen using rituximab comparedwith
concurrent control treatments in RA. However, there is a lack of
sufﬁcient long-term data to allow such a statement to be
deﬁnitively made and caution regarding infections should contin-
ue to be exercised, especially in patients who have received
repeated courses of rituximab, are receiving other immunosup-
pressants concurrently, and in thosewhose immunoglobulin levels
have fallen below the normal range. Further studies are needed to
clarify the association of rituximab with infection. Education of
physicians and patients about the association of rituximab with
infectious complications, monitoring of absolute neutrophil count
and immunoglobulin levels, identiﬁcation of high-risk groups for
the development of infectious complications, and timely vaccina-
tion of these groups are clearly needed.
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